Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Influenza viruses remain a serious public health problem. Vaccination is the most effective way to prevent the disease; however, seasonal influenza vaccines demonstrate low or no effectiveness against antigenically drifted and newly emerged influenza viruses. Different strategies of eliciting immune responses against conserved parts of various influenza virus proteins are being developed worldwide. We constructed a universal live attenuated influenza vaccine (LAIV) candidate with enhanced breadth of protection by modifying H7N9 LAIV by incorporating four epitopes of M2 protein extracellular part into its hemagglutinin molecule. The new recombinant H7N9+4M2e vaccine induced anti-M2e antibody responses and demonstrated increased protection against heterosubtypic challenge viruses in direct and serum passive protection studies, compared to the classical H7N9 LAIV. The results of our study suggest that the H7N9+4M2e warrants further investigation in pre-clinical and phase 1 clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912525 | PMC |
| http://dx.doi.org/10.3390/biomedicines9020133 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of the C protein of BVDV as a vaccine candidate: Immunoprotective studies in mice.
Vet Microbiol
September 2025
College of Animal Science and Technology/Laboratory of Functional Microbiology and Animal Health, Henan University of Science and Technology, Luoyang 471023, PR China; Luoyang Key Laboratory of Live Carrier Biomaterial and Animal Disease Prevention and Control, Henan University of Science and Techno
Bovine Viral Diarrhea Virus (BVDV) is a major pathogen associated with calf diarrhea and reproductive disorders in cattle. This study evaluated the immune-protective potential of a subunit vaccine based on the capsid C protein of the BVDV HNL-1 strain. In mice model, the C protein subunit vaccine exhibits a favorable safety and elicits robust immune-protective efficacy comparable to commercial inactivated vaccines.
View Article and Find Full Text PDFVaccination Recommendations in Patients With Atopic Dermatitis Treated With JAK Inhibitors.
Int J Dermatol
September 2025
Pfizer S.L.U, Madrid, Spain.
Atopic dermatitis therapy has undergone a revolutionary change with the introduction of Janus kinase (JAK) inhibitors. Despite their general safety profile, these immunomodulatory drugs require special precautions with respect to infection risk and vaccine administration. This document aims to provide dermatologists and other healthcare practitioners with comprehensive practical vaccination recommendations for adults and adolescent patients with atopic dermatitis who are receiving or are about to receive treatment with JAK inhibitors.
View Article and Find Full Text PDFA BtpB-Deleted Brucella Vaccine Strain Provides Dual Advantages: Enhanced Protection and Diagnostic Differentiation Capability in Mice.
Microb Biotechnol
September 2025
College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang, China.
The Brucella abortus A19 attenuated live vaccine poses potential infection risks during practical applications and interferes with serological diagnostics, thereby affecting quarantine measures and the establishment of disease-free zones. Consequently, this study aimed to reduce its potential virulence, enhance its protective efficacy and differentiate it from wild-type strains by knocking out the immunosuppressive virulence gene btpB in the A19 strain. Using homologous recombination, we successfully obtained the A19ΔBtpB deletion strain.
View Article and Find Full Text PDFManipulating Zika virus RNA tertiary structure for developing tissue-specific attenuated vaccines.
EMBO Mol Med
September 2025
State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, 100071, Beijing, China.
Traditional live attenuated vaccines (LAVs) are typically developed through serial passaging or genetic engineering to introduce specific mutations or deletions. While viral RNA secondary or tertiary structures have been well-documented for their multiple functions, including binding with specific host proteins, their potential for LAV design remains largely unexplored. Herein, using Zika virus (ZIKV) as a model, we demonstrate that targeted disruption of the primary sequence or tertiary structure of a specific viral RNA element responsible for Musashi-1 (MSI1) binding leads to a tissue-specific attenuation phenotype in multiple animal models.
View Article and Find Full Text PDFDengue virus infection reprograms baseline innate immune gene expression.
Med
September 2025
Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore 169856, Singapore; Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore; Department of Clinical Translational Research, Singapore General Hospital, Singapo
Background: All three dengue vaccines that have completed phase 3 clinical trials have shown greater efficacy in dengue-seropositive compared to dengue-seronegative individuals. This includes the live-attenuated tetravalent dengue vaccine TAK-003, where immunogenicity in baseline seronegative individuals remains lower after two doses, despite seroconversion after the first dose, compared to baseline seropositive individuals after one dose.
Methods: A whole-genome microarray was used to analyze the host response to TAK-003.